- Rezolute to Participate in the Jefferies Global Healthcare Conference
- Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)
- Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
- Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
- Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
- Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
- Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
- Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
- Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism
- Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.26 |
---|---|
High | 4.73 |
Low | 4.12 |
Bid | 4.50 |
Offer | 4.69 |
Previous close | 4.11 |
Average volume | 1.93m |
---|---|
Shares outstanding | 40.14m |
Free float | 31.95m |
P/E (TTM) | -- |
Market cap | 161.74m USD |
EPS (TTM) | -1.14 USD |
Data delayed at least 15 minutes, as of Jun 04 2024 21:00 BST.
More ▼